How Lumea Technology Delivers a 35% Reduction in Prostate Fragmentation

Abstract

This study evaluates the impact of a specialized pre-analytical stabilization workflow on the physical integrity of prostate needle core biopsies. Traditional handling methods often result in specimen fragmentation and tortuosity, leading to significant diagnostic and operational inefficiencies. Using a comparative analysis of 2,812 specimens, we demonstrate that the Lumea BxBoard® and BxChip® system reduces tissue breakage by 35% (p<0.001) and maintains superior linear orientation. These findings suggest that stabilizing tissue at the point of collection mitigates pre-analytical artifacts, optimizes downstream histopathological processing, and provides a standardized substrate for digital pathology and Artificial Intelligence (AI) integration.

Introduction

The pre-analytical phase, defined as the interval between tissue extraction and completion of fixation, accounts for up to 92.9% of all laboratory non-conformities in histopathology.¹ For prostate core biopsies specifically, the primary indicators of specimen quality are fragmentation and tortuosity (curling). Fragmentation elevates the risk of floaters and complicates cancer quantification; tortuosity introduces linear variability during microtomy, resulting in inconsistent tissue surface area at the cutting face.

Despite the downstream consequences of these pre-analytical artifacts, specimen handling at the point of collection has received comparatively little standardization. This study quantifies how a fixed-lane stabilization system, the BxBoard® and BxChip®, improves fragmentation and tortuosity metrics relative to traditional loose-core immersion in formalin.

Materials and Methods

A single-site comparative study evaluated 2,812 prostate biopsy cores across two processing protocols.

Control Group (n = 1,627): Specimens were collected via standard core needle biopsy, placed into formalin bottles for transport, and subsequently arranged in standard cassettes without positional constraint.

Experimental Group (n = 1,185): Specimens were collected and immediately placed into the dedicated lanes of the BxBoard®. Upon laboratory receipt, specimens were transitioned into the BxChip®, a tissue-mimetic matrix, for standardized processing.

Fragmentation Rate was defined as the mean number of discrete tissue breakpoints per core, identified during grossing and confirmed by digital slide review. Tortuosity Index was calculated as the ratio of the curvilinear length of the tissue to the straight-line distance between the two most distant endpoints of the core.

Fragmentation rates were compared using Poisson generalized estimating equations (GEE) with an exchangeable case-level correlation structure. Tortuosity was compared using the Mann-Whitney U test.

Results

Implementation of the Lumea workflow produced statistically significant improvements across all primary stability metrics (Table 1). Mean fragmentation decreased from 2.0 breakpoints per core in the control group to 1.3 in the experimental group, a 35% reduction. Tortuosity was similarly attenuated, with the median index falling from 1.07 (IQR 1.04–1.14) to 1.02 (IQR 1.02–1.03).

Table 1: Comparison of Specimen Stability Metrics: Traditional vs. Lumea

*Statistically significant (p<0.001).

Discussion

Mechanical Stabilization and Physics of Fixation

The reduction in fragmentation is attributable to the mechanical stabilization inherent to the BxBoard’s lane-based architecture. Traditional formalin immersion permits free core movement, subjecting tissue to fluid turbulence and mechanical friction that precipitate mid-core fractures. The BxBoard’s 0.35 mm narrow lanes provide lateral support and neutralize the kinetic energy responsible for this breakage pattern. The BxChip prevents the coiling effect that arises when tissue proteins undergo cross-linking in an unconstrained state.

Notably, even when fragmentation does occur within the BxBoard, fragments are maintained in positional sequence within the lane, preserving their identity as a single, coherent core for pathological assessment.

Diagnostic Precision: Gleason Grading and Core Length

The clinical stakes of fragmentation are substantial. Fragmented specimens compel pathologists to estimate cancer volume across multiple discrete pieces, introducing variability into Gleason scoring. This challenge is compounded by what has been termed the “diagnostic paradox”: high-grade tumors, those requiring the most precise grading, are more prone to fragmentation than lower-grade specimens.²

Core length is an independent predictor of diagnostic yield. Malignant cores are consistently longer than benign ones (mean 12.3 mm vs. 11.4 mm), and a core length exceeding 11.9 mm is associated with a 2.57-fold higher likelihood of cancer detection.⁵˒⁶ A median sample length of 12 mm is now regarded as the minimum quality assurance benchmark.⁶ Fragmentation or suboptimal sampling resulting in cores shorter than 11.4 mm significantly impairs the detection of higher-grade patterns and increases the rate of grading discordance between biopsy and radical prostatectomy specimen.⁷ By preserving linear continuity, the Lumea workflow enables more accurate assessment of maximal cancer length (MCL), a primary determinant of patient management alongside Gleason Score.

Published data contextualizes the magnitude of the fragmentation problem in conventional workflows: an overall fragmentation rate of approximately 29.3% has been reported, with the submission of multiple cores per container increasing that rate significantly.⁴ The BxBoard’s site-specific lanes directly counteract this variable by enforcing a one-core-per-lane standard.

Diagnostic Clarity: Tortuosity and ASAP

Tissue curling and tortuosity introduce mechanical compression and tangential sectioning distortion that can generate ambiguous diagnostic findings. Technical artifacts attributable to unconstrained coiling are recognized contributors to Atypical Small Acinar Proliferation (ASAP) diagnoses.⁸ Such equivocal findings trigger repeat biopsies in up to 5% of cases, a clinically and psychologically significant burden for patients.⁸ Stabilizing tissue at the point of collection reduces this source of morphological distortion, potentially increasing pathologist diagnostic confidence and reducing ASAP incidence.

Molecular Profiling and Genomic Integrity

For patients in whom genomic risk stratification is indicated, specimen integrity has direct implications for test access. Cores processed with the BxBoard are 2.1 times less likely to result in molecular test cancellation due to “Quantity Not Sufficient” (QNS) or RNA degradation (0.59% vs. 1.27%).⁹ Preserving tissue architecture at the pre-analytical stage ensures that patients can access genomic profiling without requiring additional tissue sampling, a meaningful consideration as precision oncology becomes standard of care in prostate cancer management.

Digital Pathology and AI Integration

The 35% reduction in fragmentation carries implications beyond conventional histopathology. Fragmented cores introduce edge effects that degrade the performance of AI-based grading algorithms by creating artifactual boundaries that confound tissue segmentation. Straighter, intact cores provide an optimized input for computational analysis. AI-assisted grading has already been shown to significantly increase concordance with expert Gleason grading relative to unassisted evaluation¹⁰; the specimen quality improvements described here would be expected to further enhance this pathologist-AI synergy.

Operational Impact

Standardized core orientation reduces the manual salvage work currently required during embedding of tortuous or fragmented specimens. Published data from the Lumea workflow report a 76% reduction in total laboratory processing time and an 83% reduction in embedding time.³ In high-volume urology practices, these efficiencies translate directly to throughput capacity and per-case cost.

Key Takeaways

• Fragmentation mitigation: Mechanical stabilization at the point of collection reduces core breakage by 35% compared to traditional immersion (p<0.001).
• Modifiable risk control: Submitting multiple cores in the same formalin bottle triples the fragmentation rate (14% to 41%); the BxBoard’s site-specific lanes neutralize this variable.⁴
• Gleason grading precision: Preserving linear integrity improves Gleason concordance with surgical pathology from 52.2% to 75.4%, reducing the risk of undergrading aggressive disease.⁷
• Diagnostic clarity: Stabilization prevents coiling and tangential distortion that contribute to equivocal ASAP diagnoses and unnecessary repeat biopsies.⁸
• Genomic integrity: Preserved tissue architecture reduces molecular test cancellations (QNS) by 2.1×, ensuring reliable access to precision diagnostics.⁹
• AI and digital readiness: Intact, straight specimens reduce edge-effect artifacts and optimize AI grading performance.¹⁰
• Operational efficiency: Standardized processing reduces embedding time by 83% and total laboratory processing time by 76%.³

Conclusion

The Lumea BxBoard and BxChip system reframes tissue handling as an active, protective intervention rather than a passive transport step. By significantly reducing fragmentation and tortuosity, the two primary drivers of pre-analytical specimen degradation in prostate biopsy workflows, the system establishes a new benchmark for core biopsy handling that supports diagnostic accuracy, molecular testing access, and the emerging demands of AI-integrated pathology.

Ethical Declarations

Competing Interests: This study was conducted using proprietary technology developed by Lumea. Some authors may be employees of or hold equity in Lumea, Inc. Materials were provided by the manufacturer for the purposes of this study.

Data Availability: Supporting data are available from the corresponding author upon reasonable request.

Clinical Note: The proposed biopsy core length threshold of 11.4 mm is derived from retrospective statistical analysis and should be interpreted as a quality benchmark rather than an absolute clinical mandate. Individual patient anatomy and surgeon judgment remain paramount.

References

1. Quality measures in pre-analytical phase of tissue processing: understanding its value in histopathology. J Cytol. 2016;33(1):7-11. doi:10.4103/0970-9371.175485
2. Fajardo DA, Miyamoto H, Miller JS, Netto GJ, Epstein JI. Fragmentation of prostatic needle biopsy cores containing adenocarcinoma: the role of specimen submission. Am J Surg Pathol. 2009;33(10):1472-1476. doi:10.1097/PAS.0b013e3181ad50e2
3. Murugan P, Shukla D, Morocho J, et al. Prostate biopsy processing: an innovative model for reducing cost, decreasing test time, and improving diagnostic material. Am J Clin Pathol. 2019;152(6):757-765. doi:10.1093/ajcp/aqz101
4. Shenoy K, Cote RJ, Kini G, Anthes-Bartlow M, Padmanabhan V. Is fragmentation of prostate core biopsies inevitable? A quality improvement initiative. Arch Pathol Lab Med. 2025;149(1):50-54. doi:10.5858/arpa.2023-0492-OA
5. Obek C, Dogan AS, Argun G, Kordan Y. Core length in prostate biopsy: size matters. J Urol. 2012;187(6):2051-2055. doi:10.1016/j.juro.2012.01.075
6. Fiset PO, Aprikian A, Brimo F. Length of prostate biopsy cores: does it impact cancer detection?. Can J Urol. 2013;20(4):6848-6853.
7. Guo CH, Geng YS, Zhu LY, Ding XF, Luan Y. The impact of biopsy core length on the discrepancy in Gleason scores between biopsy and radical prostatectomy specimen. BJUI Compass. 2025;6(3):e70009. Published 2025 Mar 4. doi:10.1002/bco2.70009
8. Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suggestive of prostatic adenocarcinoma. Mod Pathol. 1998;11(3):224-230.
9. Diepeveen A. Reduce test cancellation 2.1x with the BxBoard® – a case study. Lumea Technology Insights. Published November 21, 2025. Accessed February 27, 2026. https://lumeadigital.com/white-paper-tissue-standardization/
10. Bulten W, Balkenhol M, Belinga JA, et al. Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. Mod Pathol. 2021;34(3):660-671. doi:10.1038/s41379-020-0640-y

Heather Hansen R&D Research Manager and Pathologists' Assistant

Heather Hansen is a Pathologists' Assistant and R&D Research Manager at Lumea with 29 years of experience in clinical pathology, anatomical gross pathology, and laboratory leadership. She has worked hands-on in surgical and dermatopathology labs, including 11 years at the University of Utah's SOM Dermatopathology Lab, and leads the design and development of Lumea's tissue-handling products.

See Full Bio